

In the Claims:

Please cancel claims 1-36 without prejudice or disclaimer.

Please add the following claims:

37. (New) An isolated peptide 9, 10, or 11 amino acids in length comprising an oligopeptide selected from the group consisting of:

ALCRWGLLL (SEQ ID NO:12),

27 HLYQGCQVV (SEQ ID NO:14),

ILHNGAYSL (SEQ ID NO:15),

RLLQETELV (SEQ ID NO:22), and

VMAGVGSPYV (SEQ ID NO:11).

38. (New) The peptide of claim ~~37~~, wherein said oligopeptide is ALCRWGLLL (SEQ ID NO:12).

39. (New) The peptide of claim ~~37~~, wherein said oligopeptide is HLYQGCQVV (SEQ ID NO:14).

40. (New) The peptide of claim ~~37~~, wherein said oligopeptide is ILHNGAYSL (SEQ ID NO:15).

41. (New) The peptide of claim ~~37~~, wherein said oligopeptide is RLLQETELV (SEQ ID NO:22).

42. (New) The peptide of claim ~~37~~, wherein said oligopeptide is VMAGVGSPYV (SEQ ID NO:11).

43. (New) The peptide of claim ~~38~~, which is 11 amino acids in length.

44. (New) The peptide of claim ~~38~~, which is 10 amino acids in length.

45. (New) The peptide of claim ~~38~~, which is 9 amino acids in length.

46. (New) The peptide of claim ~~39~~, which is 11 amino acids in length.

47. (New) The peptide of claim ~~39~~, which is 10 amino acids in length.

48. (New) The peptide of claim ~~39~~, which is 9 amino acids in length.

49. (New) The peptide of claim ~~40~~, which is 11 amino acids in length.

50. (New) The peptide of claim ~~40~~, which is 10 amino acids in length.

51. (New) The peptide of claim ~~40~~, which is 9 amino acids in length.

52. (New) The peptide of claim ~~41~~, which is 11 amino acids in length.
53. (New) The peptide of claim ~~41~~, which is 10 amino acids in length.
54. (New) The peptide of claim ~~41~~, which is 9 amino acids in length.
55. (New) The peptide of claim ~~42~~, which is 11 amino acids in length.
56. (New) The peptide of claim ~~42~~, which is 10 amino acids in length.
57. (New) The peptide of claim ~~37~~, which is fused to a T helper peptide.
58. (New) The peptide of claim ~~37~~, which is fused to spacer or linker amino acids.
59. (New) The peptide of claim ~~37~~, which is fused to a carrier.
60. (New) The peptide of claim ~~37~~, which is linked to a lipid.
61. (New) A fusion protein comprising the peptide of claim ~~37~~.
62. (New) A homopolymer of the peptide of claim ~~37~~.
63. (New) A heteropolymer of the peptide of claim ~~37~~ and different peptides.

64. (New) A composition comprising the peptide of claim ~~37~~ and a carrier.

65. (New) A pharmaceutical composition comprising the peptide of claim ~~37~~ and a carrier.

66. (New) A composition comprising the peptide of claim ~~37~~ and a liposome.

67. (New) A vaccine comprising the peptide of claim ~~37~~ and a pharmaceutically acceptable carrier.

68. (New) A composition comprising the peptide of claim ~~37~~, and one or more other peptides.

69. (New) The composition of claim ~~68~~, wherein said peptides form a fusion protein.

70. (New) The composition of claim ~~68~~, which comprises a carrier.

71. (New) A pharmaceutical composition comprising the composition of claim ~~68~~ and a carrier.

72. (New) The composition of claim ~~68~~, wherein said peptides are fused by spacer or linker amino acids.

73. (New) A vaccine comprising the composition of claim 68 and a pharmaceutically acceptable carrier.

74. (New) An isolated peptide 9, 10, or 11 amino acids in length comprising an oligopeptide selected from the group consisting of:

KIFGSLAFL (SEQ ID NO:17),
KVAELVHFL (SEQ ID NO:18),
LVFGIELMEV (SEQ ID NO:20),
QLVFGIELMEV (SEQ ID NO:21), and
YLQLVFGIEV (SEQ ID NO:24).

75. (New) The peptide of claim 74, wherein said oligopeptide is KIFGSLAFL (SEQ ID NO:17).

76. (New) The peptide of claim 74, wherein said oligopeptide is KVAELVHFL (SEQ ID NO:18).

77. (New) The peptide of claim 74, wherein said oligopeptide is LVFGIELMEV (SEQ ID NO:20).

78. (New) The peptide of claim 74, wherein said oligopeptide is QLVFGIELMEV (SEQ ID NO:21).

79. (New) The peptide of claim ~~74~~, wherein said oligopeptide is YLQLVFGIEV
(SEQ ID NO:24).

80. (New) The peptide of claim ~~75~~, which is 11 amino acids in length.

81. (New) The peptide of claim ~~75~~, which is 10 amino acids in length.

82. (New) The peptide of claim ~~75~~, which is 9 amino acids in length.

83. (New) The peptide of claim ~~76~~, which is 11 amino acids in length.

84. (New) The peptide of claim ~~76~~, which is 10 amino acids in length.

85. (New) The peptide of claim ~~76~~, which is 9 amino acids in length.

86. (New) The peptide of claim ~~77~~, which is 11 amino acids in length.

87. (New) The peptide of claim ~~77~~, which is 10 amino acids in length.

88. (New) The peptide of claim ~~78~~, which is 11 amino acids in length.

89. (New) The peptide of claim ~~79~~, which is 11 amino acids in length.

90. (New) The peptide of claim 79, which is 10 amino acids in length.
91. (New) The peptide of claim 74, which is fused to a T helper peptide.
92. (New) The peptide of claim 74, which is fused to spacer or linker amino acids.
93. (New) The peptide of claim 74, which is fused to a carrier.
94. (New) The peptide of claim 74, which is linked to a lipid.
95. (New) A fusion protein comprising the peptide of claim 74.
96. (New) A homopolymer of the peptide of claim 74.
97. (New) A heteropolymer of the peptide of claim 74 and different peptides.
98. (New) A composition comprising the peptide of claim 74 and a carrier.
99. (New) A pharmaceutical composition comprising the peptide of claim 74 and a carrier.
100. (New) A composition comprising the peptide of claim 74 and a liposome.

101. (New) A vaccine comprising the peptide of claim 74 ~~and~~ a pharmaceutically acceptable carrier.

102. (New) A composition comprising the peptide of claim 74 ~~,~~ and one or more other peptides.

103. (New) The composition of claim 102 ~~,~~ wherein said peptides form a fusion protein.

104. (New) The composition of claim 102 ~~,~~ which comprises a carrier.

105. (New) A pharmaceutical composition comprising the composition of claim 102 ~~,~~ and a carrier.

106. (New) The composition of claim 102 ~~,~~ wherein said peptides are fused by spacer or linker amino acids.

107. (New) A vaccine comprising the composition of claim 102 ~~,~~ and a pharmaceutically acceptable carrier.

108. (New) An isolated peptide 9, 10, or 11 amino acids in length comprising the oligopeptide YMIMVKCWMI (SEQ ID NO:25).

109. (New) The peptide of claim ~~108~~, which is 11 amino acids in length.

110. (New) The peptide of claim ~~108~~, which is 10 amino acids in length.

111. (New) The peptide of claim ~~108~~, which is fused to a T helper peptide.

112. (New) The peptide of claim ~~108~~, which is fused to spacer or linker amino acids.

113. (New) The peptide of claim ~~108~~, which is fused to a carrier.

114. (New) The peptide of claim ~~108~~, which is linked to a lipid.

115. (New) A fusion protein comprising the peptide of claim ~~108~~.

116. (New) A homopolymer of the peptide of claim ~~108~~.

117. (New) A heteropolymer of the peptide of claim ~~108~~ and different peptides.

118. (New) A composition comprising the peptide of claim ~~108~~ and a carrier.

119. (New) A pharmaceutical composition comprising the peptide of claim ~~108~~ and
a carrier.

120. (New) A composition comprising the peptide of claim ~~108~~ and a liposome.

121. (New) A vaccine comprising the peptide of claim ~~108~~ and a pharmaceutically acceptable carrier.

122. (New) A composition comprising the peptide of claim ~~108~~, and one or more other peptides.

123. (New) The composition of claim ~~122~~, wherein said peptides form a fusion protein.

124. (New) The composition of claim ~~122~~, which comprises a carrier.

125. (New) A pharmaceutical composition comprising the composition of claim 122 and a carrier.

126. (New) The composition of claim ~~122~~, wherein said peptides are fused by spacer or linker amino acids.

127. (New) A vaccine comprising the composition of claim ~~122~~ and a pharmaceutically acceptable carrier.

128. (New) An isolated peptide 9, 10, or 11 amino acids in length comprising an oligopeptide selected from the group consisting of:

IMIGVLVGV (SEQ ID NO:16), and

VVLGVVFGI (SEQ ID NO:23).

129. (New) The peptide of claim ~~128~~, wherein said oligopeptide is IMIGVLVGV (SEQ ID NO:16).

130. (New) The peptide of claim ~~128~~, wherein said oligopeptide is VVLGVVFGI (SEQ ID NO:23).

131. (New) The peptide of claim ~~129~~, which is 11 amino acids in length.

132. (New) The peptide of claim ~~129~~, which is 10 amino acids in length.

133. (New) The peptide of claim ~~129~~, which is 9 amino acids in length.

134. (New) The peptide of claim ~~130~~, which is 11 amino acids in length.

135. (New) The peptide of claim ~~130~~, which is 10 amino acids in length.

136. (New) The peptide of claim ~~130~~, which is 9 amino acids in length.

137. (New) The peptide of claim 128, which is fused to a T helper peptide.
138. (New) The peptide of claim 128, which is fused to spacer or linker amino acids.
139. (New) The peptide of claim 128, which is fused to a carrier.
140. (New) The peptide of claim 128, which is linked to a lipid.
141. (New) A fusion protein comprising the peptide of claim 128.
142. (New) A homopolymer of the peptide of claim 128.
143. (New) A heteropolymer of the peptide of claim 128 and different peptides.
144. (New) A composition comprising the peptide of claim 128 and a carrier.
145. (New) A pharmaceutical composition comprising the peptide of claim 128 and a carrier.
146. (New) A composition comprising the peptide of claim 128 and a liposome.
147. (New) A vaccine comprising the peptide of claim 128 and a pharmaceutically acceptable carrier.

148. (New) A composition comprising the peptide of claim 128, and one or more other peptides.

149. (New) The composition of claim 148, wherein said peptides form a fusion protein.

150. (New) The composition of claim 148, which comprises a carrier.

151. (New) A pharmaceutical composition comprising the composition of claim 148 and a carrier.

152. (New) The composition of claim 148, wherein said peptides are fused by spacer or linker amino acids.

153. (New) A vaccine comprising the composition of claim 148 and a pharmaceutically acceptable carrier.

154. (New) The peptide of claim 57, which is fused to a PADRE® T helper peptide.

155. (New) The peptide of claim 91, which is fused to a PADRE® T helper peptide.

156. (New) The peptide of claim 111, which is fused to a PADRE® T helper peptide.

157. (New) The peptide of claim ~~137~~, which is fused to a PADRE® T helper peptide.

158. (New) The composition of claim ~~68~~, further comprising a PADRE® T helper peptide.

159. (New) The composition of claim ~~158~~, further comprising an adjuvant.

160. (New) The composition of claim ~~159~~, wherein said adjuvant is incomplete Fruends's adjuvant.

161. (New) The composition of claim ~~102~~, further comprising a PADRE® T helper peptide.

162. (New) The composition of claim ~~161~~, further comprising an adjuvant.

163. (New) The composition of claim ~~162~~, wherein said adjuvant is incomplete Fruends's adjuvant.

164. (New) The composition of claim ~~122~~, further comprising a PADRE® T helper peptide.

165. (New) The composition of claim ~~164~~, further comprising an adjuvant.

166. (New) The composition of claim ~~165~~, wherein said adjuvant is incomplete
Fruends's adjuvant.

167. (New) The composition of claim ~~148~~, further comprising a PADRE® T helper
peptide.

168. (New) The composition of claim ~~167~~, further comprising an adjuvant.

27
C
Cond
169. (New) The composition of claim ~~168~~, wherein said adjuvant is incomplete
Fruends's adjuvant.
